Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non–small-cell lung cancer (NSCLC) whose disease had prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, James C.H., Kim, Sang-We, Kim, Dong-Wan, Lee, Jong-Seok, Cho, Byoung Chul, Ahn, Jin-Seok, Lee, Dae H., Kim, Tae Min, Goldman, Jonathan W., Natale, Ronald B., Brown, Andrew P., Collins, Barbara, Chmielecki, Juliann, Vishwanathan, Karthick, Mendoza-Naranjo, Ariadna, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030895/
https://www.ncbi.nlm.nih.gov/pubmed/31809241
http://dx.doi.org/10.1200/JCO.19.00457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030895/
https://www.ncbi.nlm.nih.gov/pubmed/31809241
http://dx.doi.org/10.1200/JCO.19.00457

Ejemplares similares